C4 Therapeutics (CCCC) Current Leases (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly Current Leases of $6.5 million for Q1 2026, up 10.19% year-over-year from $5.9 million in Q1 2025, and up 2.43% quarter-over-quarter from $6.4 million in Q4 2025.
C4 Therapeutics (CCCC) Current Leases (2019 - 2026) Analysis & Trends
C4 Therapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $6.5 million for Q1 2026.
- In Q1 2026, Current Leases rose 10.19% year-over-year to $6.5 million; the TTM figure through Mar 2026 stood at $6.5 million (up 10.19% YoY), while the FY2025 annual figure was $6.4 million, up 10.27% from the prior year.
- Current Leases for Q1 2026 stood at $6.5 million, up from $6.4 million in the prior quarter.
- The five-year high for Current Leases was $6.5 million in Q1 2026, with the low at $1.7 million in Q1 2022.
- The 5-year median for Current Leases is $5.4 million (2024), against an average of $5.1 million.
- The sharpest annual moves came in 2022 and 2026: Current Leases surged 288.87% in 2022, then grew 10.19% in 2026.
- C4 Therapeutics' Current Leases stood at $4.7 million in 2022, then gained by 11.04% to $5.2 million in 2023, then gained by 10.63% to $5.8 million in 2024, then rose by 10.27% to $6.4 million in 2025, then grew by 2.43% to $6.5 million in 2026.
- Business Quant data shows CCCC's Current Leases at $6.5 million in Q1 2026, $6.4 million in Q4 2025, and $6.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - | 6.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.68 Mn |
| Mar 31, 2026 | 6.52 Mn |
| Dec 31, 2025 | 6.37 Mn |
| Sep 30, 2025 | 6.22 Mn |
| Jun 30, 2025 | 6.07 Mn |
| Mar 31, 2025 | 5.92 Mn |
| Dec 31, 2024 | 5.77 Mn |
| Sep 30, 2024 | 5.63 Mn |
| Jun 30, 2024 | 5.49 Mn |
| Mar 31, 2024 | 5.36 Mn |
| Dec 31, 2023 | 5.22 Mn |
| Sep 30, 2023 | 5.09 Mn |
| Jun 30, 2023 | 4.96 Mn |
| Mar 31, 2023 | 4.83 Mn |
| Dec 31, 2022 | 4.70 Mn |
| Sep 30, 2022 | 4.58 Mn |
| Jun 30, 2022 | 1.82 Mn |
| Mar 31, 2022 | 1.73 Mn |
| Dec 31, 2021 | 1.33 Mn |
| Sep 30, 2021 | 1.18 Mn |